IL293065A - Anti-cd154 antibodies and methods of using them - Google Patents

Info

Publication number

IL293065A

IL293065A IL293065A IL29306522A IL293065A IL 293065 A IL293065 A IL 293065A IL 293065 A IL293065 A IL 293065A IL 29306522 A IL29306522 A IL 29306522A IL 293065 A IL293065 A IL 293065A

Authority

IL

Israel

Prior art keywords

seq

antibody

residue

mutated

nos

Prior art date

2015-08-05

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title description 64
• 102100032937 CD40 ligand Human genes 0.000 claims description 205
• 101000868215 Homo sapiens CD40 ligand Proteins 0.000 claims description 195
• 230000027455 binding Effects 0.000 claims description 151
• 210000004027 cell Anatomy 0.000 claims description 118
• 239000000427 antigen Substances 0.000 claims description 85
• 108091007433 antigens Proteins 0.000 claims description 85
• 102000036639 antigens Human genes 0.000 claims description 85
• 238000006467 substitution reaction Methods 0.000 claims description 75
• 102000040430 polynucleotide Human genes 0.000 claims description 56
• 108091033319 polynucleotide Proteins 0.000 claims description 56
• 239000002157 polynucleotide Substances 0.000 claims description 56
• 229910052720 vanadium Inorganic materials 0.000 claims description 53
• 230000001404 mediated effect Effects 0.000 claims description 52
• 229910052721 tungsten Inorganic materials 0.000 claims description 50
• 229910052727 yttrium Inorganic materials 0.000 claims description 50
• 230000010118 platelet activation Effects 0.000 claims description 46
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 45
• 230000003042 antagnostic effect Effects 0.000 claims description 35
• 239000000178 monomer Substances 0.000 claims description 33
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 31
• 239000013598 vector Substances 0.000 claims description 23
• 125000000539 amino acid group Chemical group 0.000 claims description 21
• 230000004663 cell proliferation Effects 0.000 claims description 14
• 238000010494 dissociation reaction Methods 0.000 claims description 13
• 230000005593 dissociations Effects 0.000 claims description 13
• 101100099884 Homo sapiens CD40 gene Proteins 0.000 claims description 12
• 102000008212 P-Selectin Human genes 0.000 claims description 12
• 108010035766 P-Selectin Proteins 0.000 claims description 12
• 101000574441 Mus musculus Alkaline phosphatase, germ cell type Proteins 0.000 claims description 11
• 239000004218 Orcein Substances 0.000 claims description 4
• 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 3
• 229950008882 polysorbate Drugs 0.000 claims description 3
• 229920000136 polysorbate Polymers 0.000 claims description 3
• 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 claims description 2
• 229940098773 bovine serum albumin Drugs 0.000 claims description 2
• 125000003275 alpha amino acid group Chemical group 0.000 description 57
• 235000001014 amino acid Nutrition 0.000 description 43
• 230000004048 modification Effects 0.000 description 42
• 238000012986 modification Methods 0.000 description 42
• 108090000623 proteins and genes Proteins 0.000 description 36
• 238000003556 assay Methods 0.000 description 27
• 239000003814 drug Substances 0.000 description 27
• 102000004169 proteins and genes Human genes 0.000 description 27
• 238000002560 therapeutic procedure Methods 0.000 description 27
• 235000018102 proteins Nutrition 0.000 description 26
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
• 238000011282 treatment Methods 0.000 description 24
• 230000004913 activation Effects 0.000 description 22
• 230000000694 effects Effects 0.000 description 22
• 108010032595 Antibody Binding Sites Proteins 0.000 description 20
• 108060003951 Immunoglobulin Proteins 0.000 description 20
• 201000010099 disease Diseases 0.000 description 20
• 238000002474 experimental method Methods 0.000 description 20
• 102000018358 immunoglobulin Human genes 0.000 description 20
• 229940024606 amino acid Drugs 0.000 description 18
• 150000001413 amino acids Chemical class 0.000 description 18
• 208000023275 Autoimmune disease Diseases 0.000 description 17
• 210000004443 dendritic cell Anatomy 0.000 description 17
• 241001515942 marmosets Species 0.000 description 17
• 239000000203 mixture Substances 0.000 description 17
• 239000012636 effector Substances 0.000 description 16
• 238000005259 measurement Methods 0.000 description 16
• 238000002054 transplantation Methods 0.000 description 16
• 239000013638 trimer Substances 0.000 description 16
• 230000002829 reductive effect Effects 0.000 description 15
• -1 trim er Substances 0.000 description 15
• 241001465754 Metazoa Species 0.000 description 14
• 238000002296 dynamic light scattering Methods 0.000 description 14
• 239000000243 solution Substances 0.000 description 14
• 229940124597 therapeutic agent Drugs 0.000 description 14
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 12
• 230000006870 function Effects 0.000 description 12
• 238000011534 incubation Methods 0.000 description 12
• 239000000523 sample Substances 0.000 description 12
• 241000894007 species Species 0.000 description 12
• 210000004602 germ cell Anatomy 0.000 description 11
• YQNRVGJCPCNMKT-LFVJCYFKSA-N 2-[(e)-[[2-(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene]methyl]-6-prop-2-enylphenolate Chemical compound [O-]C1=C(CC=C)C=CC=C1\C=N\NC(=O)C[NH+]1CCN(CC=2C=CC=CC=2)CC1 YQNRVGJCPCNMKT-LFVJCYFKSA-N 0.000 description 10
• 108010029697 CD40 Ligand Proteins 0.000 description 10
• 101000838335 Homo sapiens Dual specificity protein phosphatase 2 Proteins 0.000 description 10
• 101001080401 Homo sapiens Proteasome assembly chaperone 1 Proteins 0.000 description 10
• 229960005552 PAC-1 Drugs 0.000 description 10
• 102100027583 Proteasome assembly chaperone 1 Human genes 0.000 description 10
• 206010003246 arthritis Diseases 0.000 description 10
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 10
• 239000012634 fragment Substances 0.000 description 10
• 208000027866 inflammatory disease Diseases 0.000 description 10
• 230000002757 inflammatory effect Effects 0.000 description 10
• 230000014759 maintenance of location Effects 0.000 description 10
• 238000002823 phage display Methods 0.000 description 10
• 206010039073 rheumatoid arthritis Diseases 0.000 description 10
• 101150013553 CD40 gene Proteins 0.000 description 9
• 239000013078 crystal Substances 0.000 description 9
• 238000005516 engineering process Methods 0.000 description 9
• 239000013604 expression vector Substances 0.000 description 9
• 230000035772 mutation Effects 0.000 description 9
• 239000008194 pharmaceutical composition Substances 0.000 description 9
• 108090000765 processed proteins & peptides Proteins 0.000 description 9
• 238000010561 standard procedure Methods 0.000 description 9
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 9
• 208000005189 Embolism Diseases 0.000 description 8
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
• 241000699670 Mus sp. Species 0.000 description 8
• 208000001435 Thromboembolism Diseases 0.000 description 8
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 8
• 238000004458 analytical method Methods 0.000 description 8
• 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 8
• 230000004071 biological effect Effects 0.000 description 8
• 239000003795 chemical substances by application Substances 0.000 description 8
• 210000004408 hybridoma Anatomy 0.000 description 8
• 230000002998 immunogenetic effect Effects 0.000 description 8
• 230000001965 increasing effect Effects 0.000 description 8
• 239000013642 negative control Substances 0.000 description 8
• 102000004196 processed proteins & peptides Human genes 0.000 description 8
• 238000003571 reporter gene assay Methods 0.000 description 8
• 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 8
• 230000003844 B-cell-activation Effects 0.000 description 7
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 7
• 241000700159 Rattus Species 0.000 description 7
• 230000020411 cell activation Effects 0.000 description 7
• 239000000539 dimer Substances 0.000 description 7
• 229940079593 drug Drugs 0.000 description 7
• 230000003993 interaction Effects 0.000 description 7
• 238000004519 manufacturing process Methods 0.000 description 7
• 229920001184 polypeptide Polymers 0.000 description 7
• 239000013641 positive control Substances 0.000 description 7
• 238000012360 testing method Methods 0.000 description 7
• 102000004127 Cytokines Human genes 0.000 description 6
• 108090000695 Cytokines Proteins 0.000 description 6
• 108020004414 DNA Proteins 0.000 description 6
• 208000009329 Graft vs Host Disease Diseases 0.000 description 6
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
• 101100365703 Mus musculus Shc4 gene Proteins 0.000 description 6
• 102000003945 NF-kappa B Human genes 0.000 description 6
• 108010057466 NF-kappa B Proteins 0.000 description 6
• 239000005557 antagonist Substances 0.000 description 6
• 230000001419 dependent effect Effects 0.000 description 6
• 238000013401 experimental design Methods 0.000 description 6
• 230000004927 fusion Effects 0.000 description 6
• 208000024908 graft versus host disease Diseases 0.000 description 6
• 229940127121 immunoconjugate Drugs 0.000 description 6
• 230000002285 radioactive effect Effects 0.000 description 6
• 238000011084 recovery Methods 0.000 description 6
• 238000012216 screening Methods 0.000 description 6
• 108020004705 Codon Proteins 0.000 description 5
• 208000028622 Immune thrombocytopenia Diseases 0.000 description 5
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 5
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
• 206010028980 Neoplasm Diseases 0.000 description 5
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 5
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 5
• 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 5
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 5
• 230000000903 blocking effect Effects 0.000 description 5
• 210000004369 blood Anatomy 0.000 description 5
• 239000008280 blood Substances 0.000 description 5
• 201000011510 cancer Diseases 0.000 description 5
• 229940127089 cytotoxic agent Drugs 0.000 description 5
• 230000016178 immune complex formation Effects 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• 102000006495 integrins Human genes 0.000 description 5
• 108010044426 integrins Proteins 0.000 description 5
• 206010025135 lupus erythematosus Diseases 0.000 description 5
• 210000002540 macrophage Anatomy 0.000 description 5
• 201000006417 multiple sclerosis Diseases 0.000 description 5
• 238000004091 panning Methods 0.000 description 5
• 230000035755 proliferation Effects 0.000 description 5
• 102000005962 receptors Human genes 0.000 description 5
• 108020003175 receptors Proteins 0.000 description 5
• 230000004044 response Effects 0.000 description 5
• 230000011664 signaling Effects 0.000 description 5
• 239000006228 supernatant Substances 0.000 description 5
• 208000024891 symptom Diseases 0.000 description 5
• 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 description 5
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
• 238000002965 ELISA Methods 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
• 238000007792 addition Methods 0.000 description 4
• 230000000890 antigenic effect Effects 0.000 description 4
• 238000013459 approach Methods 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 4
• 230000000295 complement effect Effects 0.000 description 4
• 239000003246 corticosteroid Substances 0.000 description 4
• 230000009260 cross reactivity Effects 0.000 description 4
• 238000012258 culturing Methods 0.000 description 4
• UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 4
• 239000002254 cytotoxic agent Substances 0.000 description 4
• 208000035475 disorder Diseases 0.000 description 4
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
• 239000012091 fetal bovine serum Substances 0.000 description 4
• 238000005755 formation reaction Methods 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 230000003053 immunization Effects 0.000 description 4
• 229940072221 immunoglobulins Drugs 0.000 description 4
• 230000001976 improved effect Effects 0.000 description 4
• 238000001802 infusion Methods 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 238000001990 intravenous administration Methods 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 229960003151 mercaptamine Drugs 0.000 description 4
• 210000000822 natural killer cell Anatomy 0.000 description 4
• 210000003491 skin Anatomy 0.000 description 4
• 230000001225 therapeutic effect Effects 0.000 description 4
• 210000001519 tissue Anatomy 0.000 description 4
• 108700012359 toxins Proteins 0.000 description 4
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
• 201000001320 Atherosclerosis Diseases 0.000 description 3
• 241000288950 Callithrix jacchus Species 0.000 description 3
• 241000282693 Cercopithecidae Species 0.000 description 3
• 241000196324 Embryophyta Species 0.000 description 3
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
• 239000004471 Glycine Substances 0.000 description 3
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 3
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
• 206010035226 Plasma cell myeloma Diseases 0.000 description 3
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
• 239000004473 Threonine Substances 0.000 description 3
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
• 230000002776 aggregation Effects 0.000 description 3
• 238000004220 aggregation Methods 0.000 description 3
• 235000004279 alanine Nutrition 0.000 description 3
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
• 230000003110 anti-inflammatory effect Effects 0.000 description 3
• 229940049595 antibody-drug conjugate Drugs 0.000 description 3
• 230000001363 autoimmune Effects 0.000 description 3
• 230000009286 beneficial effect Effects 0.000 description 3
• 238000010322 bone marrow transplantation Methods 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 230000030833 cell death Effects 0.000 description 3
• 238000012512 characterization method Methods 0.000 description 3
• 230000021615 conjugation Effects 0.000 description 3
• 230000000875 corresponding effect Effects 0.000 description 3
• 229960001334 corticosteroids Drugs 0.000 description 3
• 235000018417 cysteine Nutrition 0.000 description 3
• 231100000433 cytotoxic Toxicity 0.000 description 3
• 231100000599 cytotoxic agent Toxicity 0.000 description 3
• 230000001472 cytotoxic effect Effects 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 238000009792 diffusion process Methods 0.000 description 3
• 238000009826 distribution Methods 0.000 description 3
• 230000009977 dual effect Effects 0.000 description 3
• 210000003527 eukaryotic cell Anatomy 0.000 description 3
• 238000011156 evaluation Methods 0.000 description 3
• 238000000684 flow cytometry Methods 0.000 description 3
• 108020001507 fusion proteins Proteins 0.000 description 3
• 102000037865 fusion proteins Human genes 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• 238000004128 high performance liquid chromatography Methods 0.000 description 3
• XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 3
• 229960004171 hydroxychloroquine Drugs 0.000 description 3
• 239000012216 imaging agent Substances 0.000 description 3
• 230000001900 immune effect Effects 0.000 description 3
• 230000002163 immunogen Effects 0.000 description 3
• 239000003018 immunosuppressive agent Substances 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 230000005764 inhibitory process Effects 0.000 description 3
• 229960000310 isoleucine Drugs 0.000 description 3
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
• 238000006317 isomerization reaction Methods 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 239000003446 ligand Substances 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 229960000485 methotrexate Drugs 0.000 description 3
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
• 210000001616 monocyte Anatomy 0.000 description 3
• 238000002703 mutagenesis Methods 0.000 description 3
• 231100000350 mutagenesis Toxicity 0.000 description 3
• 229960004866 mycophenolate mofetil Drugs 0.000 description 3
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 3
• 201000000050 myeloid neoplasm Diseases 0.000 description 3
• 230000003472 neutralizing effect Effects 0.000 description 3
• 210000002741 palatine tonsil Anatomy 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• 238000002360 preparation method Methods 0.000 description 3
• 150000003873 salicylate salts Chemical class 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 238000001542 size-exclusion chromatography Methods 0.000 description 3
• 229960001940 sulfasalazine Drugs 0.000 description 3
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 3
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 3
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 3
• 206010043778 thyroiditis Diseases 0.000 description 3
• 239000003053 toxin Substances 0.000 description 3
• 231100000765 toxin Toxicity 0.000 description 3
• 230000009261 transgenic effect Effects 0.000 description 3
• 239000004474 valine Substances 0.000 description 3
• 239000003981 vehicle Substances 0.000 description 3
• JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
• VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
• VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
• 230000005653 Brownian motion process Effects 0.000 description 2
• 101800000267 CD40 ligand, soluble form Proteins 0.000 description 2
• 102400000432 CD40 ligand, soluble form Human genes 0.000 description 2
• 206010057248 Cell death Diseases 0.000 description 2
• 206010009900 Colitis ulcerative Diseases 0.000 description 2
• 208000011231 Crohn disease Diseases 0.000 description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
• 108010036949 Cyclosporine Proteins 0.000 description 2
• 102000053602 DNA Human genes 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 102000008946 Fibrinogen Human genes 0.000 description 2
• 108010049003 Fibrinogen Proteins 0.000 description 2
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
• 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 2
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
• 102100032999 Integrin beta-3 Human genes 0.000 description 2
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
• 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 2
• 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 2
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
• 102220588436 Keratin, type I cytoskeletal 18_S31A_mutation Human genes 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• 241000699666 Mus <mouse, genus> Species 0.000 description 2
• 238000005481 NMR spectroscopy Methods 0.000 description 2
• 241000282577 Pan troglodytes Species 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 206010057249 Phagocytosis Diseases 0.000 description 2
• XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 108700008625 Reporter Genes Proteins 0.000 description 2
• 241000219061 Rheum Species 0.000 description 2
• 108010039491 Ricin Proteins 0.000 description 2
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
• 210000001744 T-lymphocyte Anatomy 0.000 description 2
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
• PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 2
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 230000009824 affinity maturation Effects 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 239000000611 antibody drug conjugate Substances 0.000 description 2
• 239000002246 antineoplastic agent Substances 0.000 description 2
• 238000000149 argon plasma sintering Methods 0.000 description 2
• 125000003118 aryl group Chemical group 0.000 description 2
• 235000009582 asparagine Nutrition 0.000 description 2
• 229960001230 asparagine Drugs 0.000 description 2
• 229960002170 azathioprine Drugs 0.000 description 2
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 230000001588 bifunctional effect Effects 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 238000005537 brownian motion Methods 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 239000003638 chemical reducing agent Substances 0.000 description 2
• 229960001265 ciclosporin Drugs 0.000 description 2
• 230000009137 competitive binding Effects 0.000 description 2
• 230000002596 correlated effect Effects 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• 238000005859 coupling reaction Methods 0.000 description 2
• 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 2
• 229960004397 cyclophosphamide Drugs 0.000 description 2
• 229930182912 cyclosporin Natural products 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 230000016396 cytokine production Effects 0.000 description 2
• 230000009089 cytolysis Effects 0.000 description 2
• 238000007405 data analysis Methods 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 238000000113 differential scanning calorimetry Methods 0.000 description 2
• 238000006471 dimerization reaction Methods 0.000 description 2
• VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 2
• 230000001747 exhibiting effect Effects 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 239000007850 fluorescent dye Substances 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• 230000013595 glycosylation Effects 0.000 description 2
• 238000006206 glycosylation reaction Methods 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• 238000003384 imaging method Methods 0.000 description 2
• 239000012642 immune effector Substances 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 230000005847 immunogenicity Effects 0.000 description 2
• 229940121354 immunomodulator Drugs 0.000 description 2
• 229940124589 immunosuppressive drug Drugs 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 229960000681 leflunomide Drugs 0.000 description 2
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 238000002595 magnetic resonance imaging Methods 0.000 description 2
• 239000003550 marker Substances 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
• KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 2
• 229960004963 mesalazine Drugs 0.000 description 2
• 229930182817 methionine Natural products 0.000 description 2
• 229960004584 methylprednisolone Drugs 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
• 239000002773 nucleotide Substances 0.000 description 2
• 125000003729 nucleotide group Chemical group 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
• 230000008782 phagocytosis Effects 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• 238000003615 platelet activation assay Methods 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 239000002244 precipitate Substances 0.000 description 2
• 229960005205 prednisolone Drugs 0.000 description 2
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
• 229960004618 prednisone Drugs 0.000 description 2
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 238000001742 protein purification Methods 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 229960004641 rituximab Drugs 0.000 description 2
• 238000013207 serial dilution Methods 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 229960002930 sirolimus Drugs 0.000 description 2
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
• 230000009870 specific binding Effects 0.000 description 2
• 210000004989 spleen cell Anatomy 0.000 description 2
• 230000003637 steroidlike Effects 0.000 description 2
• 229910052717 sulfur Inorganic materials 0.000 description 2
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 229960001967 tacrolimus Drugs 0.000 description 2
• 230000014616 translation Effects 0.000 description 2
• 102000003390 tumor necrosis factor Human genes 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 230000003827 upregulation Effects 0.000 description 2
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
• OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
• JKHVDAUOODACDU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCN1C(=O)C=CC1=O JKHVDAUOODACDU-UHFFFAOYSA-N 0.000 description 1
• PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 1
• BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 description 1
• PMJWDPGOWBRILU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(C=C1)=CC=C1N1C(=O)C=CC1=O PMJWDPGOWBRILU-UHFFFAOYSA-N 0.000 description 1
• VLARLSIGSPVYHX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-(2,5-dioxopyrrol-1-yl)hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O VLARLSIGSPVYHX-UHFFFAOYSA-N 0.000 description 1
• WCMOHMXWOOBVMZ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCN1C(=O)C=CC1=O WCMOHMXWOOBVMZ-UHFFFAOYSA-N 0.000 description 1
• IHVODYOQUSEYJJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]amino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)C(CC1)CCC1CN1C(=O)C=CC1=O IHVODYOQUSEYJJ-UHFFFAOYSA-N 0.000 description 1
• MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 1
• DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 1
• CULQNACJHGHAER-UHFFFAOYSA-N 1-[4-[(2-iodoacetyl)amino]benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=C(NC(=O)CI)C=C1 CULQNACJHGHAER-UHFFFAOYSA-N 0.000 description 1
• PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
• YBBNVCVOACOHIG-UHFFFAOYSA-N 2,2-diamino-1,4-bis(4-azidophenyl)-3-butylbutane-1,4-dione Chemical compound C=1C=C(N=[N+]=[N-])C=CC=1C(=O)C(N)(N)C(CCCC)C(=O)C1=CC=C(N=[N+]=[N-])C=C1 YBBNVCVOACOHIG-UHFFFAOYSA-N 0.000 description 1
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
• OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
• FZDFGHZZPBUTGP-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 FZDFGHZZPBUTGP-UHFFFAOYSA-N 0.000 description 1
• FBUTXZSKZCQABC-UHFFFAOYSA-N 2-amino-1-methyl-7h-purine-6-thione Chemical compound S=C1N(C)C(N)=NC2=C1NC=N2 FBUTXZSKZCQABC-UHFFFAOYSA-N 0.000 description 1
• NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
• ZMRMMAOBSFSXLN-UHFFFAOYSA-N 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanehydrazide Chemical compound C1=CC(CCCC(=O)NN)=CC=C1N1C(=O)C=CC1=O ZMRMMAOBSFSXLN-UHFFFAOYSA-N 0.000 description 1
• ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical class O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
• 108010066676 Abrin Proteins 0.000 description 1
• 206010069754 Acquired gene mutation Diseases 0.000 description 1
• HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
• 102100022622 Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Human genes 0.000 description 1
• QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 101000651036 Arabidopsis thaliana Galactolipid galactosyltransferase SFR2, chloroplastic Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 108091008875 B cell receptors Proteins 0.000 description 1
• 244000063299 Bacillus subtilis Species 0.000 description 1
• 235000014469 Bacillus subtilis Nutrition 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
• 102100035793 CD83 antigen Human genes 0.000 description 1
• 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 description 1
• 101710132601 Capsid protein Proteins 0.000 description 1
• OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• 208000034628 Celiac artery compression syndrome Diseases 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 241001432959 Chernes Species 0.000 description 1
• 101710094648 Coat protein Proteins 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 239000004971 Cross linker Substances 0.000 description 1
• 108700032819 Croton tiglium crotin II Proteins 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• 102220496819 DNA dC->dU-editing enzyme APOBEC-3A_N57A_mutation Human genes 0.000 description 1
• WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
• 206010012442 Dermatitis contact Diseases 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 102000016607 Diphtheria Toxin Human genes 0.000 description 1
• 108010053187 Diphtheria Toxin Proteins 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 241000588921 Enterobacteriaceae Species 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 101000759376 Escherichia phage Mu Tail sheath protein Proteins 0.000 description 1
• 102220539396 Exostosin-1_Q27P_mutation Human genes 0.000 description 1
• 108010008177 Fd immunoglobulins Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 229910052688 Gadolinium Inorganic materials 0.000 description 1
• 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
• 201000005569 Gout Diseases 0.000 description 1
• 206010018634 Gouty Arthritis Diseases 0.000 description 1
• 244000041633 Grewia tenax Species 0.000 description 1
• 235000005612 Grewia tenax Nutrition 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 102000006354 HLA-DR Antigens Human genes 0.000 description 1
• 108010058597 HLA-DR Antigens Proteins 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 101000972916 Homo sapiens Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Proteins 0.000 description 1
• 101100059511 Homo sapiens CD40LG gene Proteins 0.000 description 1
• 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
• 101001037140 Homo sapiens Immunoglobulin heavy variable 3-23 Proteins 0.000 description 1
• 101001138089 Homo sapiens Immunoglobulin kappa variable 1-39 Proteins 0.000 description 1
• 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
• 101001010621 Homo sapiens Interleukin-21 Proteins 0.000 description 1
• 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
• 101001074571 Homo sapiens PIN2/TERF1-interacting telomerase inhibitor 1 Proteins 0.000 description 1
• 101001073025 Homo sapiens Peroxisomal targeting signal 1 receptor Proteins 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 208000003352 Hyper-IgM Immunodeficiency Syndrome Diseases 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 241001135301 Hypleurochilus fissicornis Species 0.000 description 1
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
• 102000009490 IgG Receptors Human genes 0.000 description 1
• 108010073807 IgG Receptors Proteins 0.000 description 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
• 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
• 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 102100040220 Immunoglobulin heavy variable 3-23 Human genes 0.000 description 1
• 102100020910 Immunoglobulin kappa variable 1-39 Human genes 0.000 description 1
• 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
• 101710149643 Integrin alpha-IIb Proteins 0.000 description 1
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
• ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 1
• 208000003456 Juvenile Arthritis Diseases 0.000 description 1
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
• 102220588695 Keratin, type I cytoskeletal 18_S53A_mutation Human genes 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• 239000004201 L-cysteine Substances 0.000 description 1
• 235000013878 L-cysteine Nutrition 0.000 description 1
• 208000005777 Lupus Nephritis Diseases 0.000 description 1
• 241000282567 Macaca fascicularis Species 0.000 description 1
• 101710125418 Major capsid protein Proteins 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
• 102220486635 Mannose-1-phosphate guanyltransferase beta_S56A_mutation Human genes 0.000 description 1
• ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
• 244000302512 Momordica charantia Species 0.000 description 1
• 235000009811 Momordica charantia Nutrition 0.000 description 1
• 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• WTBIAPVQQBCLFP-UHFFFAOYSA-N N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O Chemical compound N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O WTBIAPVQQBCLFP-UHFFFAOYSA-N 0.000 description 1
• BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 108091028043 Nucleic acid sequence Proteins 0.000 description 1
• 101710141454 Nucleoprotein Proteins 0.000 description 1
• 102100036257 PIN2/TERF1-interacting telomerase inhibitor 1 Human genes 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
• 101100413173 Phytolacca americana PAP2 gene Proteins 0.000 description 1
• 241000047875 Pica hudsonia Species 0.000 description 1
• 241000235648 Pichia Species 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
• 101710083689 Probable capsid protein Proteins 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 108010076504 Protein Sorting Signals Proteins 0.000 description 1
• 102220477329 Protein XRP2_S28A_mutation Human genes 0.000 description 1
• 241000589516 Pseudomonas Species 0.000 description 1
• 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 208000033464 Reiter syndrome Diseases 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 241000235070 Saccharomyces Species 0.000 description 1
• 241000607142 Salmonella Species 0.000 description 1
• 241000607720 Serratia Species 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 230000037453 T cell priming Effects 0.000 description 1
• 229940123237 Taxane Drugs 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 102000006601 Thymidine Kinase Human genes 0.000 description 1
• 108020004440 Thymidine kinase Proteins 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 241000469816 Varus Species 0.000 description 1
• 240000001866 Vernicia fordii Species 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 102220546633 Voltage-dependent L-type calcium channel subunit beta-2_L54A_mutation Human genes 0.000 description 1
• 102220580702 Voltage-dependent T-type calcium channel subunit alpha-1H_N52A_mutation Human genes 0.000 description 1
• 102220582435 Voltage-dependent T-type calcium channel subunit alpha-1H_N59A_mutation Human genes 0.000 description 1
• 102220580956 Voltage-dependent T-type calcium channel subunit alpha-1H_S30A_mutation Human genes 0.000 description 1
• IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 108010076089 accutase Proteins 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 229960002964 adalimumab Drugs 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 238000012867 alanine scanning Methods 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 108010001818 alpha-sarcin Proteins 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
• 239000012491 analyte Substances 0.000 description 1
• 229940045799 anthracyclines and related substance Drugs 0.000 description 1
• 239000003430 antimalarial agent Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 108010044540 auristatin Proteins 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• 244000052616 bacterial pathogen Species 0.000 description 1
• 210000003651 basophil Anatomy 0.000 description 1
• 229960003270 belimumab Drugs 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 229940022836 benlysta Drugs 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 229960002537 betamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
• 238000013357 binding ELISA Methods 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 230000006287 biotinylation Effects 0.000 description 1
• 238000007413 biotinylation Methods 0.000 description 1
• 210000001772 blood platelet Anatomy 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 238000009933 burial Methods 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 235000011148 calcium chloride Nutrition 0.000 description 1
• 229930195731 calicheamicin Natural products 0.000 description 1
• HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
• 239000005018 casein Substances 0.000 description 1
• BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
• 235000021240 caseins Nutrition 0.000 description 1
• 229960000590 celecoxib Drugs 0.000 description 1
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 238000001516 cell proliferation assay Methods 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000008614 cellular interaction Effects 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 229940044683 chemotherapy drug Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 239000013611 chromosomal DNA Substances 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 229960002842 clobetasol Drugs 0.000 description 1
• CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 238000012875 competitive assay Methods 0.000 description 1
• 230000024203 complement activation Effects 0.000 description 1
• 108010047295 complement receptors Proteins 0.000 description 1
• 102000006834 complement receptors Human genes 0.000 description 1
• 238000010668 complexation reaction Methods 0.000 description 1
• 150000001875 compounds Chemical class 0.000 description 1
• 239000000562 conjugate Substances 0.000 description 1
• 208000010247 contact dermatitis Diseases 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 239000007822 coupling agent Substances 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 150000001945 cysteines Chemical class 0.000 description 1
• 238000004163 cytometry Methods 0.000 description 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
• 230000009615 deamination Effects 0.000 description 1
• 238000006481 deamination reaction Methods 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 230000022811 deglycosylation Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 238000004925 denaturation Methods 0.000 description 1
• 230000036425 denaturation Effects 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 229940000033 dermatological agent Drugs 0.000 description 1
• 239000003241 dermatological agent Substances 0.000 description 1
• 230000000368 destabilizing effect Effects 0.000 description 1
• 230000001066 destructive effect Effects 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 229930191339 dianthin Natural products 0.000 description 1
• 229960001259 diclofenac Drugs 0.000 description 1
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
• 125000005442 diisocyanate group Chemical group 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• ZLFRJHOBQVVTOJ-UHFFFAOYSA-N dimethyl hexanediimidate Chemical compound COC(=N)CCCCC(=N)OC ZLFRJHOBQVVTOJ-UHFFFAOYSA-N 0.000 description 1
• 206010013023 diphtheria Diseases 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
• 229960003668 docetaxel Drugs 0.000 description 1
• AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
• 229930188854 dolastatin Natural products 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 230000007783 downstream signaling Effects 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 108010028531 enomycin Proteins 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 229960005293 etodolac Drugs 0.000 description 1
• XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
• 231100000776 exotoxin Toxicity 0.000 description 1
• 239000002095 exotoxin Substances 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 229940012952 fibrinogen Drugs 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 229960000785 fluocinonide Drugs 0.000 description 1
• 150000002222 fluorine compounds Chemical class 0.000 description 1
• 229960002390 flurbiprofen Drugs 0.000 description 1
• SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 239000012737 fresh medium Substances 0.000 description 1
• 238000002825 functional assay Methods 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 102000034238 globular proteins Human genes 0.000 description 1
• 108091005896 globular proteins Proteins 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• 150000004676 glycans Chemical group 0.000 description 1
• 125000003827 glycol group Chemical group 0.000 description 1
• 229960001743 golimumab Drugs 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 229960002706 gusperimus Drugs 0.000 description 1
• 229940115747 halobetasol Drugs 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 238000001794 hormone therapy Methods 0.000 description 1
• 229940048921 humira Drugs 0.000 description 1
• 230000004727 humoral immunity Effects 0.000 description 1
• 229960000890 hydrocortisone Drugs 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 206010066130 hyper-IgM syndrome Diseases 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• 150000002463 imidates Chemical class 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 230000014726 immortalization of host cell Effects 0.000 description 1
• 230000006058 immune tolerance Effects 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 230000003308 immunostimulating effect Effects 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 230000001861 immunosuppressant effect Effects 0.000 description 1
• 238000002650 immunosuppressive therapy Methods 0.000 description 1
• 230000002637 immunotoxin Effects 0.000 description 1
• 229940051026 immunotoxin Drugs 0.000 description 1
• 239000002596 immunotoxin Substances 0.000 description 1
• 231100000608 immunotoxin Toxicity 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 229960000598 infliximab Drugs 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 108010074108 interleukin-21 Proteins 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 230000031146 intracellular signal transduction Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 229930027917 kanamycin Natural products 0.000 description 1
• 229960000318 kanamycin Drugs 0.000 description 1
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
• 229930182823 kanamycin A Natural products 0.000 description 1
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
• 229960000991 ketoprofen Drugs 0.000 description 1
• 238000012933 kinetic analysis Methods 0.000 description 1
• 238000012004 kinetic exclusion assay Methods 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 229950005692 larotaxel Drugs 0.000 description 1
• SEFGUGYLLVNFIJ-QDRLFVHASA-N larotaxel dihydrate Chemical compound O.O.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@@]23[C@H]1[C@@]1(CO[C@@H]1C[C@@H]2C3)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 SEFGUGYLLVNFIJ-QDRLFVHASA-N 0.000 description 1
• 229960004942 lenalidomide Drugs 0.000 description 1
• GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 238000002898 library design Methods 0.000 description 1
• 230000029226 lipidation Effects 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 230000001050 lubricating effect Effects 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 230000002101 lytic effect Effects 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 238000009115 maintenance therapy Methods 0.000 description 1
• 229910052748 manganese Inorganic materials 0.000 description 1
• 239000011572 manganese Substances 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 229960001929 meloxicam Drugs 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 229950000844 mizoribine Drugs 0.000 description 1
• 108010010621 modeccin Proteins 0.000 description 1
• 238000000302 molecular modelling Methods 0.000 description 1
• 238000002625 monoclonal antibody therapy Methods 0.000 description 1
• 210000004980 monocyte derived macrophage Anatomy 0.000 description 1
• 238000000569 multi-angle light scattering Methods 0.000 description 1
• 229960000951 mycophenolic acid Drugs 0.000 description 1
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
• IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 description 1
• 229960004270 nabumetone Drugs 0.000 description 1
• 229960002009 naproxen Drugs 0.000 description 1
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• 150000007523 nucleic acids Chemical class 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• BWKDAMBGCPRVPI-ZQRPHVBESA-N ortataxel Chemical compound O([C@@H]1[C@]23OC(=O)O[C@H]2[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]2(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]21)OC(C)=O)C3(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC(C)C)C(=O)C1=CC=CC=C1 BWKDAMBGCPRVPI-ZQRPHVBESA-N 0.000 description 1
• 229950001094 ortataxel Drugs 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 229960002739 oxaprozin Drugs 0.000 description 1
• OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
• 239000003002 pH adjusting agent Substances 0.000 description 1
• 238000012856 packing Methods 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000013618 particulate matter Substances 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 230000006320 pegylation Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 210000001539 phagocyte Anatomy 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• 238000009521 phase II clinical trial Methods 0.000 description 1
• 108010076042 phenomycin Proteins 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
• 235000011007 phosphoric acid Nutrition 0.000 description 1
• 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 229960002702 piroxicam Drugs 0.000 description 1
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
• 238000002616 plasmapheresis Methods 0.000 description 1
• 239000013600 plasmid vector Substances 0.000 description 1
• 238000007747 plating Methods 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 150000004804 polysaccharides Chemical group 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
• 235000019833 protease Nutrition 0.000 description 1
• 231100000654 protein toxin Toxicity 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 230000005180 public health Effects 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 208000002574 reactive arthritis Diseases 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 229940116176 remicade Drugs 0.000 description 1
• 230000003252 repetitive effect Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 229960000371 rofecoxib Drugs 0.000 description 1
• RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
• 102200016465 rs104894275 Human genes 0.000 description 1
• 102220040126 rs371657037 Human genes 0.000 description 1
• 102200011361 rs727502767 Human genes 0.000 description 1
• 102220280441 rs776730435 Human genes 0.000 description 1
• 239000012146 running buffer Substances 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 229940068638 simponi Drugs 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• MKNJJMHQBYVHRS-UHFFFAOYSA-M sodium;1-[11-(2,5-dioxopyrrol-1-yl)undecanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCCCCCCN1C(=O)C=CC1=O MKNJJMHQBYVHRS-UHFFFAOYSA-M 0.000 description 1
• ULARYIUTHAWJMU-UHFFFAOYSA-M sodium;1-[4-(2,5-dioxopyrrol-1-yl)butanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O ULARYIUTHAWJMU-UHFFFAOYSA-M 0.000 description 1
• MIDXXTLMKGZDPV-UHFFFAOYSA-M sodium;1-[6-(2,5-dioxopyrrol-1-yl)hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O MIDXXTLMKGZDPV-UHFFFAOYSA-M 0.000 description 1
• RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 1
• 230000037439 somatic mutation Effects 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 238000010911 splenectomy Methods 0.000 description 1
• 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 238000012289 standard assay Methods 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 238000000547 structure data Methods 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 239000000126 substance Substances 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 229960000894 sulindac Drugs 0.000 description 1
• MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• MODVSQKJJIBWPZ-VLLPJHQWSA-N tesetaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3CC[C@@]2(C)[C@H]2[C@@H](C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C(=CC=CN=4)F)C[C@]1(O)C3(C)C)O[C@H](O2)CN(C)C)C(=O)C1=CC=CC=C1 MODVSQKJJIBWPZ-VLLPJHQWSA-N 0.000 description 1
• 229950009016 tesetaxel Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 229960003433 thalidomide Drugs 0.000 description 1
• 230000010512 thermal transition Effects 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
• 230000036962 time dependent Effects 0.000 description 1
• RUELTTOHQODFPA-UHFFFAOYSA-N toluene 2,6-diisocyanate Chemical compound CC1=C(N=C=O)C=CC=C1N=C=O RUELTTOHQODFPA-UHFFFAOYSA-N 0.000 description 1
• 239000003860 topical agent Substances 0.000 description 1
• 230000005030 transcription termination Effects 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 102000035160 transmembrane proteins Human genes 0.000 description 1
• 108091005703 transmembrane proteins Proteins 0.000 description 1
• 229960005294 triamcinolone Drugs 0.000 description 1
• GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
• YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
• LEHFPXVYPMWYQD-XHIJKXOTSA-N ulobetasol Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]2(C)C[C@@H]1O LEHFPXVYPMWYQD-XHIJKXOTSA-N 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 229960004355 vindesine Drugs 0.000 description 1
• UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 238000003260 vortexing Methods 0.000 description 1
• XLYOFNOQVPJJNP-OUBTZVSYSA-N water-17o Chemical compound [17OH2] XLYOFNOQVPJJNP-OUBTZVSYSA-N 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 238000002424 x-ray crystallography Methods 0.000 description 1
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1